louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01601288: Database of All Patients Who Have Undergone Pulmonary Function Testing at Singapore General Hospital
Official title: Prospective Database of All Patients Who Have Undergone Pulmonary Function Testing at Singapore General Hospital
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Obstructive Pulmonary Diseases
Restrictive Lung Disease
Cough
Dyspnea
Keywords: obstructive lung disease
restrictive lung disease
cough
dyspnea
Lead sponsor: Singapore General Hospital
Sponsor class: OTHER
First posted: 2012-05-17
Enrollment: 17000
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Prospective data collection of all patients who have undergone pulmonary function testing at Singapore General Hospital

Brief summary: The purpose of this study is to create a prospective database of all patients who have undergone pulmonary function testing from which the investigators can study the clinical phenotypes of various respiratory conditions. The investigators hope by understanding the differences in these myriad phenotypes to be able to provide individualized, patient-targeted therapy in the future.

Detailed description: Recent studies have shown that clinical phenotyping of patients with various respiratory conditions is important in the understanding of the disease process, clinical response to treatment, and prognosis. Pulmonary function testing is a very important aspect of clinical phenotyping in many respiratory conditions. Creating a database will enable us to study the various phenotypes within each respiratory condition. This will allow us to better understand each disease, with a view to provide personalized patient care targeted at their specific phenotype and hence better clinical outcomes.

Eligibility criteria: Inclusion Criteria:

1) All patients who have undergone pulmonary function testing at the Singapore General Hospital pulmonary function laboratory

Primary outcomes:
measure: Diagnoses based on pulmonary function test interpretation
timeFrame: 7 days
Secondary outcomes:
Other outcomes:
Locations:
city: Singapore
country: Singapore
facility: Singapore General Hospital
Study officials:
affiliation: Singapore General Hospital
name: Su Ying Low, BMBCh
role: PRINCIPAL_INVESTIGATOR
References:
citation: Nishimura M, Makita H, Nagai K, Konno S, Nasuhara Y, Hasegawa M, Shimizu K, Betsuyaku T, Ito YM, Fuke S, Igarashi T, Akiyama Y, Ogura S; Hokkaido COPD Cohort Study Investigators. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012 Jan 1;185(1):44-52. doi: 10.1164/rccm.201106-0992OC.
citation: Nathan SD, Shlobin OA, Weir N, Ahmad S, Kaldjob JM, Battle E, Sheridan MJ, du Bois RM. Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest. 2011 Jul;140(1):221-229. doi: 10.1378/chest.10-2572.
Clinical trial NCT03954288: The Serum Sclerostin Levels in Cholesteatoma Patients
Official title: The Serum Sclerostin Levels in Cholesteatoma Patients
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Otitis Media Chronic
Cholesteatoma
Keywords: otitis media chronic
cholesteatoma
sclerostin
Lead sponsor: Abant Izzet Baysal University
Sponsor class: OTHER
First posted: 2019-05-17
Enrollment: 75
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: The experimental group of this study consisted of 75 patients who applied to AIBU Bolu Izzet Baysal Training and Research Hospital Ear Nose Throat Clinic and regularly followed up. A control group of approximately 50 people, which is demographically similar, and patients whose scheduled for operation with other causes.

Brief summary: The aim of this study is to investigate the levels of sclerostin in patients with cholesteatoma. So far, there is no study showing the levels of sclerostin in cholesteatoma. The investigators hope that the results of our study will start new processes that can be used in the clinic.

Detailed description: Chronic otitis media (COM) is the perforation of the eardrum and mucosal inflammation of the space in the middle ear and the air cavities of the temporal bone over a period of three months. Although COM is defined as a multifactorial disease, its etiopathogenesis has not been fully elucidated. Cholesteatoma is a condition that disrupts the balance between bone formation and resorption in COM. The cholesteatoma is a destructive squamous epithelial lesion of temporal bone, it gradually expands and leads to serious complications by the destruction of near bone structures, ossicular chain and otic capsule. A growing debate examines the role of bone formation and destruction with osteoblasts, osteocytes and osteoclast cells in cholesteatoma formation. Sclerostin is a glycoprotein that plays a role in the regulation of bone metabolism secreted by osteocytes. Antibodies directed against sclerostin stimulate bone formation and represent a new therapeutic option for the treatment of increased bone resorption diseases, such as osteoporosis and generalized bone loss, inflammatory diseases with cartilage damage. The aim of this study is to investigate the levels of sclerostin in patients with cholesteatoma. So far, there is no study showing the levels of sclerostin in cholesteatoma. The investigators hope that the results of our study will start new processes that can be used in the clinic.

Eligibility criteria: Inclusion Criteria:

cholesteatoma chronic otitis media

Exclusion Criteria:

Acute infection Malignancy

Primary outcomes:
measure: change of the levels of sclerostin in cholesteatoma at 1 month
timeFrame: 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: Bolu
country: Turkey
facility: Özgür Mehmet Yis
state: Merkez
Study officials:
References:
Clinical trial NCT00354588: Arterial Stiffness, Wave Reflections and Renal Failure
Official title: Observational Study on the Prognostic Significance (Renal and Cardiovascular) of Arterial Stiffness and Arterial Wave Reflections in Patients With Mild to Moderate Renal Impairment
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Chronic Renal Failure
Arterial Stiffness
Arterial Wave Reflections
Keywords: chronic renal failure
arterial stiffness
arterial wave reflections
Lead sponsor: Klinikum Wels-Grieskirchen
Sponsor class: OTHER
First posted: 2006-07-20
Enrollment: 115
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with chronic renal failure

Brief summary: 1. Cardiovascular risk is high in patients with renal failure.
2. Cross-sectional studies have indicated a relationship between arterial stiffness and renal function. However, there are no prospective longitudinal studies in the literature.
3. In dialysis patients, arterial stiffness as well as wave reflections, predict mortality. However, there are no data on patients with mild-to-moderate renal impairment available.
4. Therefore, we designed a study to test the hypothesis that: a) measures of arterial stiffness and wave reflections predict the progression of renal impairment in patients with mild-to-moderate renal failure; and b) measures of arterial stiffness and wave reflections predict cardiovascular events in patients with mild-to-moderate renal failure


Eligibility criteria: Inclusion Criteria:

* chronic renal failure patients (KDOQI III, IV) undergoing regular control visits at our nephrology department
* \> 19 years
* written informed consent

Exclusion Criteria:

* atrial fibrillation
* valvular heart disease
* severely impaired systolic function
* no informed consent

Primary outcomes:
measure: renal endpoint
Secondary outcomes:
Other outcomes:
Locations:
city: Wels
country: Austria
facility: Cardiology and Nephrology Department Klinikum Wels
Study officials:
affiliation: Cardiology Department, Klinikum Wels, Austria
name: Thomas Weber, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Nephrology Department, Klinikum Wels, Austria
name: Manfred Wallner, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01222988: Improving Maintenance Following Very Low Calorie Diet: The Sustain Lost Weight (SLW) Intervention
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2010-10-18
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: Obtain a preliminary assessment of the feasibility and acceptability of delivering the sustained lost weight (SLW) intervention in a real-world clinical setting for patients who have completed a 21-week very low calorie diet (VLCD).

Hypothesis: Intervention will be feasible to implement as evidenced by the ability to recruit and retain participants and acceptable to participants as evidenced by self-report of satisfaction with the program and adoption of weight maintenance behaviors.

Secondary Aim: Obtain a preliminary assessment of the effectiveness of the sustained lost weight (SLW) intervention for patients who have completed 21 weeks of a very low calorie diet (VLCD).

Hypothesis: Greater than 75% of participants who receive this novel approach, where maintenance behaviors are individualized based on resting metabolic rate and a physical activity factor, will regain greater or equal to 10 kg. at week 52 follow-up.


Eligibility criteria: Inclusion Criteria:

* Completed fast and transition period of the OPTIFAST® program
* Be able to participate fully in all aspects of the study
* Willing to refrain from participating in additional weight loss interventions for the duration of the study
* Willing to provide written informed consent.

Exclusion Criteria:

* Myocardial infarction within 6 months
* Unstable angina
* Stroke
* Chronic steroid use
* Active peptic ulcer disease
* Advanced cirrhosis
* Active hepatitis
* Advanced renal disease
* Active thrombophlebitis
* Recent skeletal fractures
* Use of lithium
* Pancreatitis
* Pregnancy
* Type 1 diabetes mellitus
* History of diabetic ketoacidosis
* Active bulimia nervosa
* Severe depression
* Psychosis
* Substance abuse

Primary outcomes:
measure: Treatment Feasibility
timeFrame: 52 weeks
Secondary outcomes:
measure: Weight Gain Analysis
timeFrame: 52 weeks
Other outcomes:
Locations:
city: Jacksonville
country: United States
facility: Mayo Clinic
state: Florida
Study officials:
affiliation: Mayo Clinic
name: Gretchen Ames, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05550688: Weight Gain After Smoking Cessation and NAFLD
Official title: The Effect of Weight Gain After Smoking Cessation Increased the Risk of Type 2 Diabetes in Individuals With Nonalcoholic Fatty Liver Disease
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Nonalcoholic Fatty Liver Disease
Type 2 Diabetes
Lead sponsor: Ningbo No. 1 Hospital
Sponsor class: OTHER
First posted: 2022-09-22
Enrollment: 12941
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The investigators enrolled participants who took annual health examinations at Zhenhai Lianhua Hospital in 2007.

Brief summary: Nonalcoholic fatty liver disease (NAFLD) is rapidly becoming the most common chronic liver disease. Considering that there are no approved pharmacological treatments, lifestyle modification is necessary and challenging to reduce the risk of type 2 diabetes mellitus (T2DM) in patients with NAFLD.

Cigarette smoking has a significant negative impact on public health, causing more than 480,000 deaths each year. Smoking has been reported as a risk factor for NAFLD and might accelerate liver disease progression. Therefore, it is recommended that patients with NAFLD quit smoking. However, smoking cessation could be complicated by weight gain. Thus, it is important to assess the impact of weight change after smoking cessation on patients with NAFLD. Proper management of post-cessation weight could maximize its health benefits.

In this large-scale cohort study, the investigators aimed to assess the effects of smoking cessation and subsequent weight change on risks of incident T2DM in individuals with NAFLD.


Eligibility criteria: Inclusion Criteria:

(i) age\>=18 years.

Exclusion Criteria:

(i) with missing information on ultrasound, smoking status, and weight; (ii) with excess alcohol intake or history of chronic liver disease at baseline; (iii) female subjects.

Primary outcomes:
measure: Weight Change after smoking cessation on incident T2DM in NAFLD individuals
timeFrame: a 7-year cohort study
measure: Weight Change after smoking cessation on incident T2DM in NAFLD-free individuals
timeFrame: a 7-year cohort study
Secondary outcomes:
measure: Mediation analysis of smoking relapse on incident T2DM
timeFrame: a 7-year cohort study
Other outcomes:
Locations:
city: Ningbo
country: China
facility: Ningbo first hospital
state: Zhejiang
Study officials:
References:
Clinical trial NCT04916288: Needle Puncture Point During Central Venous Catheterization With Ultrasound Guidance
Official title: Position of Puncture Point of the Introducer Needle During Internal Jugular Venous Catheterization With Ultrasound Guidance
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Central Venous Catheterization
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
Collaborators: name: SMG-SNU Boramae Medical Center
First posted: 2021-06-07
Enrollment: 112
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patients (\>18 years old) scheduled to elective surgery requiring central venous catheterization under general anesthesia.

Brief summary: In this observational study, we will measure the shortest distance from the cricoid cartilage level to the puncture site of the introducer needle when anesthesiologists perform central venous catheterization.

Detailed description: After anesthesia induction and tracheal intubation, we will prepare central venous catheterization for patients requiring it. After anesthesiologists who are blinded to this study perform central venous catheterization, an investigator measured the shortest distance from the crease line of the cricoid cartilage to the puncture site of the introducer needle.

Eligibility criteria: Inclusion Criteria:

* elective surgery under general anesthesia
* requirement of central venous catheterization

Exclusion Criteria:

* disagreement for participation

Primary outcomes:
measure: puncture site
timeFrame: intraoperative
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul Metropolitan Government Seoul National University Boramae Medical Center
Study officials:
affiliation: SMG-SNU Boramae Medical Center
name: Jung-Man Lee, MD.PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01088893: Everolimus in Breast Cancer Patients After Pre-operative Chemotherapy
Official title: A Randomized Study of mTOR Inhibition by RAD001 (Everolimus) in Invasive Breast Cancer Patients After Pre-operative Use of Anthracycline and/or Taxane-based Chemotherapy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Breast Neoplasms
Keywords: everolimus
neoadjuvant
m-TOR inhibitor
Lead sponsor: Organisation for Oncology and Translational Research
Sponsor class: OTHER
First posted: 2010-03-17
Enrollment: 50
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a randomized controlled pilot study investigating signals involved in drug resistance to chemotherapy.

Patient will be randomized to undergo observation or to receive Everolimus after completion of neoadjvuant treatment (anthracycline and/or taxane-based) and before surgery. The patients will be monitored for efficacy and safety.


Eligibility criteria: Inclusion Criteria:

* Women aged ≥ 18 years;
* Histologically and/or cytologically confirmed invasive ductal or lobular breast cancer;
* Tumor of 3 cm or greater at time of diagnosis
* Measurable primary tumor after neoadjuvant treatment before randomization
* No prior chemotherapy for breast cancer;
* ECOG performance status ≤1 or Karnofsky performace status ≥ 70%
* Adequate liver/renal function
* Able to swallow whole tablets.
* Able to give written informed consent
* Able to follow prescription instructions reasonably well

Exclusion Criteria:

* Male patient
* Prior history of other malignancy within 5 years of study entry, aside from contralateral breast carcinoma, appropriately treated cervical carcinoma in situ, or adequately treated basal or squamous cell carcinoma of the skin
* Distant metastasis, including skin involvement beyond the breast area
* Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration, or which, in the judgment of the investigator, would make the patient inappropriate for entry into this study

Primary outcomes:
measure: measure change of biomarkers in pre- and post- surgery samples
timeFrame: baseline and 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: Hong Kong
country: China
facility: Unimed Medical Institute
Study officials:
References:
Clinical trial NCT06487793: Mobile App Intervention for Sleep Problems and Alcohol Use Among Veterans
Official title: A Mobile App to Address Co-Occurring Sleep Problems and Heavy Alcohol Use Among Veterans Outside of Care Settings
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Alcohol Use Disorder
Insomnia
Lead sponsor: University of Southern California
Sponsor class: OTHER
Collaborators: name: RAND
name: Palo Alto Veterans Institute for Research
name: University of Missouri-Columbia
First posted: 2024-07-05
Enrollment: 130
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to test the preliminary efficacy of a brief mobile app targeting insomnia symptoms among veterans. In this study, we will enhance the mobile app, Insomnia Coach, with content from brief alcohol interventions to help veterans reduce both insomnia symptoms and alcohol use behaviors. We will compare those veterans who are randomly assigned to receive this brief mobile app intervention to those who receive a control condition. This will help us determine if veterans randomly assigned to receive the intervention experience greater improvement on outcomes compared to those who do not receive the intervention. The study involves a beta-test phase of the app to ensure feasibility and acceptability by veterans, followed by a randomized controlled trial with 130 veterans who meet criteria for insomnia and alcohol use disorder.


Eligibility criteria: Inclusion Criteria:

* U.S. veteran aged 18 or older separated or discharged from service in the Air Force, Army, Marine Corps, Navy, or Coast Guard
* Not currently affiliated with active duty service or on active reserves or guard service
* Served since September 11, 2001
* No past 6-month treatment for alcohol or drug use or insomnia
* Alcohol Use Disorder Identification Test (AUDIT) score of 8 or higher
* Insomnia Severity Index (ISI) score of 10 or higher

Exclusion Criteria:

* Positive screening for other substance use disorders (not including cannabis use disorder)

Primary outcomes:
measure: Insomnia symptoms
timeFrame: Past 30 days
measure: Alcohol use frequency
timeFrame: Past 30 days
measure: Alcohol use quantity
timeFrame: Past 30 days
Secondary outcomes:
measure: Sleep quality
timeFrame: Past 30 days
measure: Alcohol-related consequences
timeFrame: Past 30 days
Other outcomes:
measure: Treatment initiation
timeFrame: Past 30 days
Locations:
Study officials:
References:
Clinical trial NCT06639893: Crestal Bone Loss in Mandibular Telescopic Overdentures. Overdenture with Milled Titanium, Milled Poly-ether Ketone Ketones and 3D Printed Chrome Cobalt Secondary Copings.
Official title: Crestal Bone Loss in Mandibular Telescopic Implant Retained Overdenture with Milled Titanium, Milled Poly-ether Ketone Ketones and 3D Printed Chrome Cobalt Secondary Copings
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Telescopic Overdentures
Dental Implants
Customized Abutments
Lead sponsor: Cairo University
Sponsor class: OTHER
Collaborators: name: Minia University
First posted: 2024-10-15
Enrollment: 30
Sex: ALL
Minimum age (years): 55
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objective of this clinical trial is to evaluate crestal bone loss every three months at time of overdenture insertion, 3, 6, 9, 12 months from overdenture use. Also, to evaluate prosthesis satisfaction.

All participants will receive conventional complete dentures, followed by two intraforaminal implants. After healing time, fabrication of secondary copings in all cases according to randomized groups for final overdenture insertion.


Eligibility criteria: Inclusion Criteria:

1. Sufficient remaining bone in height, width and thickness in the interforaminal area to allow installation of at least 3.3 mm diameter and 8 mm length implants.
2. Adequate amount of interarch space of at least 12mm.
3. Age range from 55 to 75 years old age.

Exclusion Criteria:

1. Systemic and metabolic diseases that may affect osseointegration.
2. Patients receiving bisphosphonates therapy.
3. Patients under radiotherapy or chemotherapy.

Primary outcomes:
measure: Crestal bone loss.
timeFrame: one year
Secondary outcomes:
Other outcomes:
Locations:
city: El minia
country: Egypt
facility: EL Minia University
Study officials:
References: